V S Goldmacher

1.1k total citations
15 papers, 947 citations indexed

About

V S Goldmacher is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, V S Goldmacher has authored 15 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 7 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in V S Goldmacher's work include Toxin Mechanisms and Immunotoxins (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Transgenic Plants and Applications (5 papers). V S Goldmacher is often cited by papers focused on Toxin Mechanisms and Immunotoxins (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Transgenic Plants and Applications (5 papers). V S Goldmacher collaborates with scholars based in United States. V S Goldmacher's co-authors include JM Lambert, W A Blättler, Thomas F. Tedder, N Spector, F Coral, L Eliseo, Albert R. Collinson, Lee M. Nadler, John M. Lambert and KC Anderson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

V S Goldmacher

15 papers receiving 921 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V S Goldmacher United States	14	516	374	371	257	253	15	947
Maria-Ana Ghetie United States	14	376 0.7×	330 0.9×	261 0.7×	216 0.8×	178 0.7×	16	692
Gregory L. Moore United States	18	432 0.8×	649 1.7×	639 1.7×	318 1.2×	71 0.3×	42	1.2k
Thelma M. Watson United States	9	590 1.1×	181 0.5×	200 0.5×	310 1.2×	82 0.3×	9	754
Irene Leung United States	13	444 0.9×	621 1.7×	625 1.7×	252 1.0×	61 0.2×	30	1.2k
A. Lagarde Canada	10	165 0.3×	138 0.4×	362 1.0×	255 1.0×	71 0.3×	19	706
Fabrice Le Gall Germany	16	356 0.7×	650 1.7×	495 1.3×	356 1.4×	96 0.4×	20	998
Samir Tawadros Germany	16	352 0.7×	142 0.4×	254 0.7×	225 0.9×	48 0.2×	34	863
Masako Wakitani Japan	14	696 1.3×	1.4k 3.8×	1.5k 4.1×	219 0.9×	204 0.8×	15	1.8k
Laurel A. Eckhardt United States	19	783 1.5×	367 1.0×	675 1.8×	98 0.4×	30 0.1×	37	1.2k
Yun‐Feng Piao China	7	347 0.7×	70 0.2×	376 1.0×	222 0.9×	45 0.2×	10	845

Countries citing papers authored by V S Goldmacher

Since Specialization

Citations

This map shows the geographic impact of V S Goldmacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V S Goldmacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V S Goldmacher more than expected).

Fields of papers citing papers by V S Goldmacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V S Goldmacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V S Goldmacher. The network helps show where V S Goldmacher may publish in the future.

Co-authorship network of co-authors of V S Goldmacher

This figure shows the co-authorship network connecting the top 25 collaborators of V S Goldmacher. A scholar is included among the top collaborators of V S Goldmacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V S Goldmacher. V S Goldmacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Han, Jianfeng, et al.. (1997). p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc.. PubMed. 57(1). 176–82. 47 indexed citations

Vater, Carol A., et al.. (1996). Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts.. PubMed. 13(4). 739–48. 37 indexed citations

O’Connor, Rosemary, Cheng‐Che Liu, Yali Liu, et al.. (1995). Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood. 86(11). 4286–4294. 34 indexed citations

Goldmacher, V S, et al.. (1994). Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments]. Blood. 84(9). 3017–3025. 62 indexed citations

Roguska, Michael, Andrew Henry, Stephen Searle, et al.. (1994). Humanization of murine monoclonal antibodies through variable domain resurfacing.. Proceedings of the National Academy of Sciences. 91(3). 969–973. 159 indexed citations

Goldmacher, V S, et al.. (1994). Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments]. Blood. 84(9). 3017–3025. 56 indexed citations

Goldmacher, V S, et al.. (1993). The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13.. The Journal of Immunology. 151(6). 2915–2927. 99 indexed citations

Grossbard, Michael L., JM Lambert, V S Goldmacher, et al.. (1993). Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.. Journal of Clinical Oncology. 11(4). 726–737. 128 indexed citations

Freedman, AS, Jerome Ritz, F Coral, et al.. (1992). Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 79(3). 576–585. 131 indexed citations

10.

Freedman, AS, Jerome Ritz, F Coral, et al.. (1992). Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 79(3). 576–585. 8 indexed citations

11.

Lambert, JM, V S Goldmacher, Albert R. Collinson, Lee M. Nadler, & W A Blättler. (1991). An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.. PubMed. 51(23 Pt 1). 6236–42. 103 indexed citations

12.

Goldmacher, V S, et al.. (1989). Realizing the full potential of immunotoxins.. PubMed. 1(2). 50–5. 13 indexed citations

13.

Tedder, Thomas F., V S Goldmacher, JM Lambert, & Stuart F. Schlossman. (1986). Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.. The Journal of Immunology. 137(4). 1387–1391. 36 indexed citations

14.

Goldmacher, V S, et al.. (1986). Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.. The Journal of Immunology. 136(1). 320–325. 15 indexed citations

15.

Goldmacher, V S, Janet Anderson, W A Blättler, JM Lambert, & Peter D. Senter. (1985). Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins.. The Journal of Immunology. 135(6). 3648–3651. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact